Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
2024
· University of Michigan,
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service
This study evaluated the cost-effectiveness of using nirsevimab to prevent respiratory syncytial virus (RSV) in infants and high-risk children. By analyzing healthcare data, it was …
Ask aRCie
Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States [Dataset]
This dataset provides monthly estimates of infant protection against RSV that were calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). The data …
A Framework for Monitoring RSV Prevention Product Effectiveness in the United States
This article outlines a framework for CDC's RSV immunization effectiveness program, focusing on evaluating current immunization policy, informing future policy, boosting confidence in immunization, and …
Elucidating the Outpatient Burden of RSV Disease in Children
This commentary refers to an article titled "Burden of RSV Infections Among Young Children in Primary Care: A Prospective Cohort Study in Five European Countries …
Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness
2024
· University of Michigan,
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service
This study evaluates the benefits and cost-effectiveness of a vaccine for pregnant women to protect babies from RSV, a virus that can cause serious illness …
Nirsevimab Coverage, Children 0 to 7 months, United States
The report describes how nirsevimab coverage for infants 0 to 7 months is tracked in the U.S. using data from Immunization Information Systems (IIS). It …
Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024
2024
· New York City Department of Health and Mental Hygiene,
· Centers for Disease Control and Prevention (CDC)
This analysis reviewed nirsevimab dosing based on Vaccines for Children (VFC) eligibility in New York City during the 2023–24 RSV season. A nirsevimab shortage in …
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower RespiratoryTract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United Sta
This article discusses the use of Pfizer's RSV vaccine for pregnant women to protect infants from RSV-related lung disease. The CDC recommends giving the vaccine …
ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8–19 Months of Age at Increased Risk of Severe Disease Entering Their Second RSV Season
This webpage provides evidence for the recommendations made by the Advisory Committee on Immunization Practices (ACIP) for the use of nirsevimab for a population of …
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
2024
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service,
· University of Rochester,
· University of Cincinnati,
· Cincinnati Children's Hospital Medical Center,
· Vanderbilt University,
· Texas Children's Hospital,
· Baylor College of Medicine,
· University of Washington,
· University of Pittsburgh,
· Children's Mercy Kansas City
This study looks at the impact of respiratory syncytial virus (RSV) in young children during the 2023-2024 season. It describes how two new RSV prevention …